Impact of metabolic syndrome in the control of blood pressure and dyslipemia;Importancia del síndrome metabólico en el control de la presión arterial y de la dislipemia

Medicina Clinica

Volumn 123, Issue 16, 2004, Pages 601-605

  Rodilla, Enrique ^a   García, Luis ^a   Merino, Consolación ^a   Costa, José A ^a   González, Carmen ^b   Pascual, José M ^a,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL DE SAGUNTO   (Spain)

^c Hospital de Sagunt   (Spain)

Author keywords

Blood pressure; Dyslipemia; Metabolic syndrome

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CALCULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; REGRESSION ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 10644243544     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13068434     Document Type: Article

References (29)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-96.
2. Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
3. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dislipemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
4. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk if coronary heart disease: the Framingham study. Ann Intern Med 1971;74:1-12.
5. Multiple Risk Factor Intervention Trial Research Group. Multiple risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982;248:1465-77.
6. Grundy SM, Balady GJ, Cirquie MH, Fletcher G, Greenland P, Hirarzka LF et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association task Force on Risk Reduction. Circulation 1997;95:1683-5.
7. Liese AD, Mayer-Davis EF, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 1998; 20:157-72.
8. Park YW, Shankuan Z, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome. Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-36.
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanem LK, Kumpsusalo E, Romilento J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged man. JAMA 2002;288:2709-16.
10. Pyorala M, Miettinem H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22 years follow-up results of the Helsinki Policemen Study. Circulation 1998;98:398-404.
11. Pyorala M, Miettinem H, Laakso M. Plasma insulin and all-cause, cardiovascular and noncardiovascular mortality. The 22-year follow-up results of the Helsinky Policemen Study. Diabetes Care 2000;23:1097-102.
12. Alvarez León EE, Ribas Barba L, Serra Majem L. Prevalencia del síndrome metabólico en la población de las Islas Canarias. Med Clin (Barc) 2003;120:172-4.
13. Hernández A, Riera C, Solá E, Oliver MJ, Martínez ML, Morillas C, et al. Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica. Med Clin (Barc) 2003;121:204-8.
14. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Valls J, Carmena R. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population Eur J Intern Med 2003;14:101-6.
15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.
16. Petrie JC, O'Brien ET, Littler WA, De Swiet M; British Hypertension Society. Recommendations on blood pressure measurement. Br Med J 1986;293:611-5.
17. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood pressure. Arch Intern Med 1997;157:2413-46.
18. Friedewald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low-density lipoproteins cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. Hill JO, Bessesen D. Wat to do about metabolic syndrome. Arch Inter Med 2003;163:395-7.
20. Tuornilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Finish Diabetes Prevention Study Group: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
21. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
22. Komers R, Vrana A. Thiazolidinediones: tools for the research of metabolic syndrome X. Physiol Res 1998;47:215-25.
23. Martens FM, Visseren FL, Lemay J, DeKoning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62: 1463-80.
24. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesäniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999;245:163-74.
25. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108:1546-51.
26. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159:1104-9.
27. Brotons C, Cascant P, Ribera A, Moral I, Permanyer G. Utilidad de la medición del riesgp coronario a partir de la ecuación del estudio de Framingham: estudio de casos y controles. Med Clin (Barc) 2003;121:327-30.
28. Zimrnet P. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Trends Cardiovasc Med 2002;12:354-62.
29. Reusch JE. Current concepts in insulin resistance, type2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002;90(Suppl):19-26.